Drug Approval & Reimbursement in 2026

• Keytruda SC Tops New NHI Listing Round with 75 Billion Yen Sales Outlook
  November 9, 2026

• Imulrio Finally Set for NHI Listing after 296-Day Wait; Zero Rule Strikes Again
  October 8, 2026

• Japan Approves Keytruda, Leqembi SC Formulations, Xcopri, and More Drugs
  September 17, 2026

• Japan Approves Takeda’s Orzeyful, Insmed’s Brinsupri and More Drugs
  August 25, 2026

• Trazenta Draws 8 Generic Entrants as Japan Clears New DPP-4 Copies
  August 17, 2026

• Sarclisa SC, Joenja, Kineret, and 7 More Drugs Bound for NHI Listing
  August 6, 2026

• Chuikyo Clears NHI Listing for Oncolys’ Telomelysin
  August 6, 2026

• Chuikyo OKs NHI Listing for Cuorips’ iPSC-Based Riheart
  July 23, 2026

• Boehringer’s Big-Seller Hopeful Jascayd Set for Listing, Haihe’s Haizexin Too
  July 9, 2026

• Chuikyo OKs NHI Listing for Ferring’s Adstiladrin, Ishin’s Allostem Sheet
  July 9, 2026

• Japan Approves Wegovy MASH Use, AstraZeneca’s Etcamah, Others
  June 22, 2026

• Revolade, Bilanoa See First Generics in June Listing; 3 Final AGs on Roster
  June 11, 2026

• Japan Approves Oncolys’ Telomelysin for Esophageal Cancer
  June 8, 2026

• Japan Approves Jascayd, mNEXSPIKE, Zepbound OSA Use, Others
  May 19, 2026

• Japan OKs Coverage for Susmed Insomnia App, Shionogi ADHD Therapy App
  May 15, 2026

• Japan OKs Listing of Ambelvist, Dojolvi, Sohonos, and Finally Inrebic
  May 14, 2026

• Chuikyo Clears NHI Listing for Amchepry, Akuugo, and Zolgensma Intrathecal
  May 14, 2026

• Ferring Nabs Japan Approval for Bladder Cancer Gene Therapy
  May 12, 2026

• Japan OKs Listing of Exdensur, Aquipta, Tukysa, and More; New Price Rules Applied to Two
  April 9, 2026

• Japan OKs Zolgensma Intrathecal Form, Breyanzi Expansion, New EB Therapy
  April 6, 2026

ページ